文献速递急腹症与外科感染围术期管理与 ERAS

烧伤患者既往GLP-1受体激动剂暴露与临床结局的关联

Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients.
PubMed 文献 · Br J Surg · 2026-01-01

基于TriNetX美国协作网络的回顾性队列研究,纳入热烧伤面积≤20%TBSA的成人患者,经倾向评分匹配后每组8307例。既往1年内使用GLP-1受体激动剂与1年死亡率降低54%、ICU入院减少35%、插管减少62%相关,感染并发症亦显著减少;3年队列中肥厚性瘢痕风险增加27%。

要点

  • 既往GLP-1受体激动剂暴露与烧伤患者死亡率、感染并发症及重症监护使用显著降低相关。
  • 获益独立于BMI等代谢因素,且在6个月和3年暴露窗口的敏感性分析中持续存在。
  • 需警惕3年队列中肥厚性瘢痕风险增加27%,仍需前瞻性研究验证。

核心结论

  • 既往GLP-1受体激动剂使用与烧伤患者死亡率、感染并发症及重症监护使用显著降低相关,独立于BMI等代谢因素。

研究设计与样本

  • 将烧伤前1年内有GLP-1受体激动剂使用记录的患者与对照按年龄、性别、种族、合并症、TBSA、BMI和HbA1c进行倾向评分匹配,每组8307例。
  • 敏感性分析考察6个月和3年暴露窗口。

主要发现

  • GLP-1受体激动剂暴露与死亡率降低54%相关(OR 0.46,P < 0.001)。
  • ICU入院减少35%(OR 0.65,P < 0.001),插管减少62%(OR 0.38,P < 0.001)。
  • 感染并发症显著减少:脓毒症减少32%、肺炎减少24%、MRSA感染减少27%;广谱抗生素使用减少21%。
  • 3年队列中肥厚性瘢痕增加27%(OR 1.27,P = 0.031)。
  • 获益在所有暴露窗口(6个月、1年、3年)中持续存在。

临床怎么用

  • 对于烧伤前使用GLP-1受体激动剂的患者,围术期管理可关注其潜在的重症监护需求降低和感染风险下降。
  • 需在烧伤患者随访中警惕肥厚性瘢痕风险,尤其长期暴露者。

局限性

  • 回顾性队列设计,可能存在残余混杂。
  • 研究结论需前瞻性研究验证以优化围术期管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and immunomodulatory properties beyond glycaemic control. The impact of GLP-1 receptor agonists on burn injury outcomes remains unexplored. The aim of this study was to assess the potential impact of prior GLP-1 receptor agonist exposure on mortality, infectious complications, and critical care utilization in burn patients. METHODS: Using the TriNetX US Collaborative Network, adult patients with thermal burns ≤20% total body surface area (TBSA) between 1 January 2018 and 8 November 2025 were identified. Patients with documented GLP-1 receptor agonist use within 1 year before burn injury were propensity score matched with controls for age, sex, race, co-morbidities, TBSA, BMI, and haemoglobin A1c (HbA1c). Outcomes included 1-year mortality, infectious complications, critical care utilization, and wound management outcomes. Sensitivity analyses examined 6-month and 3-year exposure windows. RESULTS: After matching, 8307 patients per cohort were included. GLP-1 receptor agonist exposure was associated with 54% reduced odds of mortality (OR 0.46, P < 0.001), 35% reduced intensive care unit admission (OR 0.65, P < 0.001), and 62% reduced intubation (OR 0.38, P < 0.001). Infectious complications were significantly decreased, including sepsis (32% reduction), pneumonia (24% reduction), and methicillin-resistant Staphylococcus aureus (MRSA) infection (27% reduction). The odds of broad-spectrum antibiotic use decreased 21%. Benefits persisted across all exposure windows. The 3-year cohort demonstrated a 27% increase in hypertrophic scarring (OR 1.27, P = 0.031). CONCLUSION: Prior GLP-1 receptor agonist use was associated with a significant decrease in mortality, infectious complications, and critical care utilization among burn patients, independent of metabolic factors like BMI. These findings warrant prospective studies to optimize perioperative management strategies in this patient population. Glucagon-like peptide-1 (GLP-1) drugs are used to treat diabetes and help with weight loss. These drugs are also known to reduce inflammation in the body. However, how these drugs affect healing after burn injuries is not known. This study aimed to find out whether burn patients who were taking GLP-1 medications before being injured had better outcomes. Health records from over 400 000 burn patients in the USA were studied. Patients on GLP-1 drugs were compared with similar patients not on these drugs. Burn patients on GLP-1 drugs were less likely to die, get bad infections, or need intensive care and more research is needed to assess the use of these drugs in this patient population.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Boukind A, Sharma AC, Henriquez MJ, et al. Clinical outcomes associated with prior glucagon-like peptide-1 receptor agonist exposure in burned patients. Br J Surg. 2026. PMID: 42003114. doi:10.1093/bjs/znag048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。